Expression and Functional Analysis of Human Mutated Relaxin-2
CSEF · 2013 Pharmacology/ Toxicology
Overview
Objectives/Goals In this project we attempt to design and obtain in Pichia pastoris a functional recombinant human Relaxin-2 with mutations reducing the binding specificity toward RXFP2, but preserving the binding to RXFP1, for pharmaceutical purposes. Methods/Materials Pichia pastoris was induced by 3% Methanol, with cell density at 30~35 OD600nm, and for 24 hours. Proteins in the supernatant were separated by SDS-PAGE was detected on the membrane using a specific anti-His antibody. The protein was purified through a TALON column. The purified protein was then cleaved by thrombin to produce the mature mutated human Relaxin-2 protein. The CHO cells were transfected with empty vector or the vectors carrying RXFP1 or RXFP2 gene by lipofectamine. Recombinant mutated human Relaxin-2 was added to the cells with a final concentration of 1nM. The cAMP was detected by ELISA. Results 1. Recombinant mutated human Relaxin-2 can be expressed and secreted in the Pichia pastoris system. 2. The purity of recombinant mutated human Relaxin-2 is over 98% after affinity purification. 3. Under the physiological concentration, 1mM recombinant mutated human Relaxin-2 can significantly activate RXFP1 receptor resulting in an accumulation of cAMP. However, there is not obvious difference of the RXFP2 expressed cells and Control cells in cAMP level. Conclusions/Discussion In this study, we successfully expressed and purified a mutated human Relaxin-2 from Pichia pastoris. This mutated human Relaxin-2 can significantly activate the cells with expression of RXFP1 receptor, but not RXFP2, suggesting selective activation of RXFP1 by the mutated Relaxin-2. However, our study does not provide direct ligand-receptor binding evidence thus we cannot exclude the binding possibility between the mutated human Relaxin-2 and RXFP2. Addressing this question and examining the cardioprotective functions of the mutated human Relaxin-2 in animal models will be our next focus.
Summary statement
It have designed and produced a mutated human Relaxin-2 that preferrally activates RXFP1
Help received
Used lab at Newcca corporation under the supervision of Dr. Wenbin Tan
Competition history
- CSEF 2013
Resources
Related projects
CSEF · 2010
In vitro Analysis of a Synthetic Protein: A Model for Enzyme Replacement Therapy
CSEF · 2003
Regulation of Receptor Expression by Thyroid Hormone and Methoprene Acid
ISEF · 2017
The Effect of Mutations in the Ligand Binding Pocket on the Function of Ftz F1
CSEF · 2013
Improving Binding Affinity of the Calbindin-D9k Protein to Develop Efficient Calcium Biosensors
CSEF · 2017
Developing a Tool for Studying Alzheimer's: A Bacterial Expression Vector for the M3-M4 Fragment of the nAChR alpha-7
CSEF · 2011
Therapeutic Natural Products: Effect of H36A Mutation on Structure and Function of StfQ
ISEF · 2025
Novel Fusion Protein Approach to Cardiovascular Disease With Computational Modelling
ISEF · 2023
Purification of the MED1 Receptor Interaction Domain
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: California Science & Engineering Fair public projects